![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Sunday, July 01, 2018 4:57:38 PM
http://www.pnas.org/content/112/11/E1297
My words, a great unmet need. They are going off label to try and get cures on some of these bad diseases.
10 times more powerful can make a big difference if all goes well here. Prior TX did not get the right drug in a right combination.
4 to 6 hours of treatment vs. a possibly home TX.
I had not read the abstract closely until today and I was impressed on how much there is a need for this drug to come through. There is no other drug out there that can do what we might be able to do if we get approval. All thus in my interpretation of reading the abstract.
I hope MNTA bangs this big time.
Frankly, I am excited if they can pull this one off. No one else has the patents and we can take over the market with an approval and improve patient outcomes on over 84 potential diseases with future approvals.
Boing X 2
FEATURED ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM